Clinical Trial Update: Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing fulvestrant plus placebo versus fulvestrant plus palbociclib as first-line therapy for postmenopausal HR-positive advanced breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Neoplasms

Drugs mentioned

• Fulvestrant (fulvestrant)
• Palbociclib (palbociclib)

Snippet

Sponsor: Spanish Breast Cancer Research Group | Conditions: Breast Neoplasms | Phase 2 | Status: UNKNOWN